A Phase 2/3 interventional study of BHV-7000 and Placebo in Generalized Epilepsy, sponsored by Biohaven Therapeutics Ltd.. Terminated at 109 sites in 14 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Biohaven Therapeutics Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Epilepsy, Idiopathic Generalized with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Epilepsy, Idiopathic Generalized · United States.
Among the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States, this one is the 12th largest by enrollment of the 14 interventional ones that give a count, is the only one that started in 2024, is the only one in phase 2/3, and was the 15th registered.
35 studies on the registry are indexed under Epilepsy, Idiopathic Generalized; 4 are open to participants now.
Browse Epilepsy, Idiopathic Generalized studies →2 of the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States are open now. Recruiting first, the newest first:
Praxis Precision Medicines · Sites in United States, Australia, Spain
Ages 18–75
Oregon Health and Science University · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 3 Epilepsy, Idiopathic Generalized studies recruiting now, none set no upper age limit and 3 stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 5 · Phase 3 5 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2024.
This study's enrollment of 27 is below the median of 71 across 26 interventional studies indexed under Epilepsy, Idiopathic Generalized.
Median enrollment 61 across the 14 interventional studies, 316 across the 3 observational. Of the 15 that completed or were terminated, 8 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 10 most frequent:
Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Biohaven Therapeutics Ltd. has 1 study filed under Epilepsy, Idiopathic Generalized — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Epilepsy, Idiopathic Generalized with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of idiopathic generalized epilepsy with generalized tonic-clonic seizures and includes an additional open-label extension (OLE) phase.
35 studies on the registry are indexed under Epilepsy, Idiopathic Generalized; 4 are open to participants now.
This study's enrollment of 27 is below the median of 71 across 26 interventional studies indexed under Epilepsy, Idiopathic Generalized.
Browse Epilepsy, Idiopathic Generalized studies →Biohaven Therapeutics Ltd. is the lead sponsor of 20 studies on the registry; 9 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Compared within Epilepsy, Idiopathic Generalized, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy, Generalized. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Diagnosis of Idiopathic Generalized Epilepsy at least 6 months prior to the screening visit, defined by 2017 International League Against Epilepsy (ILAE) Classification and based on requirements of Epilepsy Adjudication criteria.
Exclusion Criteria:
Drug: BHV-7000
Drug: Placebo
BHV-7000 75mg. Participants will take blinded investigational product (IP) once daily
Matching placebo taken once daily
Time to the Second Day with a Generalized Tonic Clonic (GTC) Seizure During the 24- week Double-blind Treatment Period
To compare the efficacy of BHV-7000 to placebo as adjunctive therapy for subjects with idiopathic generalized epilepsy with generalized tonic-clonic (GTC) seizures as measured by the time to the second day with a GTC seizure during the double-blind phase
Time frame: Baseline to Week 24 of Double-Blind Treatment Period
Percentage of Participants with freedom of GTC seizures during DBT Phase
To compare the efficacy of BHV-7000 to placebo in terms of the proportion of subjects that are free of GTC seizures as measured by the proportion of subjects with GTC seizure freedom during the 24-week DBP, estimated using Kaplan- Meier methods.
Time frame: Baseline to Week 24 of Double-Blind Treatment Period
Number of Participants With Deaths, Serious AEs (SAEs), AEs Leading to Study Drug Discontinuation, and moderate or severe AEs
To assess the safety and tolerability of BHV-7000 as measured by the number of unique subjects with deaths, SAEs, AEs leading to discontinuation, and moderate and severe AEs
Time frame: Baseline to Week 24 of Double-Blind Treatment Period
Number of Participants With Clinically Significant Laboratory Abnormalities
To assess the safety and tolerability of BHV-7000 as measured by the number of unique subjects with grade 3 and grade 4 laboratory abnormalities.
Time frame: Baseline to Week 24 of Double-Blind Treatment Period
Showing the first 100 of 109 sites across 14 countries. Choose a country and city above to see the rest.
Ran from Jun 2024 to primary completion in Mar 2026, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Opakalim
Epilepsy, Idiopathic Generalized →
Biohaven Therapeutics Ltd.